CAV1 and neoplasm: Cav-1 and other markers of the RWE represent promising targets for new combinations of therapies that work by ’uncoupling’ tumor cells from CAFs by preventing stromal Cav-1 degradation [35–39] which may also have the ability to attenuate immunosuppression for immune therapies.